

Bożena Cybulska-Stopa, Karolina Piejko, Renata Pacholczak, Małgorzata Domagała-Haduch, Anna Drosik-Kwaśniewska, Agata Sałek-Zań, Patrycja Wiktor-Mucha, Janusz Rolski, Tomasz Zemełka

Clinical Oncology Clinic, Maria Skłodowska-Curie National Research Institute of Oncology, Cracow Branch, Poland

Immunotherapy or targeted therapy as first-line treatment of patients with advanced/metastatic melanoma with the *BRAF* mutation — a single-center analysis

Address for correspondence:

Dr n. med. Bożena Cybulska-Stopa
Klinika Onkologii Klinicznej
Narodowy Instytut Onkologii
im. M. Skłodowskiej-Curie
— Państwowy Instytut Badawczy
Oddział w Krakowie
e-mail: bcybulskastopa@vp.pl

Oncology in Clinical Practice
2020, Vol. 16, No. x
DOI: 10.5603/OCP.2020.0023
Translation: prof. Ewa Bartnik
Copyright © 2020 Via Medica
ISSN 2450–1654

ABSTRACT

Introduction. One of the most important achievements of contemporary oncology is the discovery of new therapeutic possibilities: targeted therapy and immunotherapy associated with checkpoint inhibitors. It has not been unequivocally determined so far which therapy should be used as first-line treatment in patients with advanced/metastatic melanoma with the *BRAF* mutation.

Material and methods. 137 patients with advanced/metastatic melanoma with the *BRAF* mutation were analyzed. They received anti-PD1-1 therapy (IT) or molecularly targeted therapy iBRAF ± iMEK (TT) as first-line treatment in the scope of the national drug program. IT and TT therapies used as first-line treatment were compared.

Results. Median OS and PFS in the group were 14.0 and 7.3 months. Unfavorable prognostic factors for OS and PFS were metastases to the central nervous system, increased LDH levels and performance status > 1. Metastatic sites in > 2 locations were only unfavorable prognostic factors for OS. A statistically significant difference was found between TT and IT for OS ($p = 0.0011$; median for TT was 12.6 months and was not reached for IT). It should be noted that the group treated with TT was characterized by a worse prognostic factors. No differences in PFS were observed ($p = 0.292$, medians 7.2 and 9.0 months, respectively).

Conclusion. In patients with advanced/metastatic melanoma with a *BRAF* mutation without rapid progression, IT should be considered as first-line therapy.

Key words: melanoma, immunotherapy, targeted therapy, sequential therapy, *BRAF* mutation

Oncol Clin Pract 2020; 16

Introduction

In recent years treatment of patients with a melanoma diagnosis has changed greatly. The presence of specific mutations in melanoma cells, including the *BRAF* [1] mutation, was discovered. The *BRAF V600* mutation is present in approximately 50% of patients with metastatic melanoma and is a predictive factor for response to targeted therapies [2]. The use of targeted therapies

with inhibitors of BRAF ± MEK (iBRAF ± iMEK) has contributed to a considerable improvement of the treatment results in respect to overall survival (OS) and progression-free survival (PFS) which has been confirmed in randomized trials [3–8]. Moreover, the development of immunotherapy associated with immune checkpoint inhibitors (ICIs) has improved the results of treatment of melanoma patients [9–18]. ICI action is independent of the presence of the *BRAF* mutation

[16–19]. Administration of ICIs may lead to long-term remission [8–16]. The dominant problem, however, is the low percentage of responses to immune checkpoint inhibitors as well as the length of time from the moment of initiating the therapy to the response to treatment [9–16]. The response to targeted therapies is different, as the percentage of responses to treatment is high and the time to response is very short [3–8].

Systemic treatment of patients with the *BRAF* mutation poses a significant therapeutic challenge. So far the therapy which should be applied as first-line treatment has not been determined unequivocally in patients with advanced/metastatic melanoma. There is little data on this subject and the results of randomized trials, which would directly compare the effectiveness of anti-PD-1 immunotherapy (IT) and targeted therapy *iBRAF* ± *iMEK* (TT) as first-line treatment in this group of patients are missing [20–26]. Currently, two clinical studies are ongoing DREMseg (NCT02224781) and SECOMBIT (NCT02631447) and EORTC EBIN which should answer to this question but the results are still awaited [27].

Therefore we decided to undertake a retrospective analysis comparing first-line TT or IT treatment in patients with advanced/metastatic melanoma with a *BRAF* mutation. The paper presents the analysis of 137 patients with advanced/metastatic melanoma with a *BRAF* mutation who received immunotherapy or targeted therapy as first-line treatment.

Material and methods

All patients with advanced/metastatic melanoma treated in the frame of national drug programs from January 2013 to June 2019 in the Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Cracow branch were analyzed. 137 patients from the group with the *BRAF* mutation who had received IT or TT as first-line treatment were selected from this group. First-line IT treatment in patients with the *BRAF* mutation in the scope of national drug programs was initiated in 2017 as then new indications were included. In all analyzed patients data were collected concerning age, sex, location of the primary tumor, stage of the disease and type of therapy used as first, second and subsequent line. Information concerning the stage of the disease, metastasis location, lactate dehydrogenase (LDH) levels (LDH) and ECOG (Eastern Cooperative Oncology Group) performance status [17] were collected at the start of systemic first-line treatment.

Statistical analysis

To determine the *p* value of defined factors between the group treated with IT and the larger group treated with TT Fisher's exact test was used. The final

points encompassed evaluation of progression-free survival (PFS), overall survival (OS) and evaluation of the overall response rate (ORR) and disease control rate (DCR) defined by the criteria of response evaluation RECIST 1.1. PFS or OS were calculated from the beginning of IT or TT to disease progression according to RECIST, death or the last documented contact. The Kaplan-Meier method was used to evaluate PFS and OS with a 95% confidence interval (CI) and survival curves were analyzed by log-rank analysis. The Cox proportional hazard model was used to evaluate, in a multidimensional model, the significance of the effect of prognostic variables on PFS and OS at the moment of initiation IT or TT therapy. Differences are considered significant if $p < 0.05$. All statistical analyses were performed using the STATISTICA 12 program.

Results

General characteristics of the analyzed group

In the group of 137 patients with advanced/metastatic melanoma with the *BRAF* mutation 110 (80%) patients received first-line TT therapy and 27 (20%) IT. TT in 45 (41%) patients was *iBRAF* (vemurafenib or dabrafenib) and in 65 (55%) *iBRAF* + *iMEK* (vemurafenib + cobimetinib or dabrafenib + trametinib). Before 2017, 64 patients received TT treatment. As IT anti-PD-1 (nivolumab or pembrolizumab) was used. 57 (42%) patients received second line treatment, among them 39 patients received the IT-TT sequence and 4 patients the TT-IT sequence. In the group receiving the TT-IT sequence, the second line treatment was nivolumab or pembrolizumab (19 patients) and ipilimumab (20 patients). In the IT-TT group, the second line treatment in all patients was *iBRAF* + *iMEK*. Third line and fourth line treatment were administered to 15 (11%) patients and 3 (2%) patients, respectively. In the group receiving TT, there were statistically significantly more patients with metastases to the CNS, elevated LDH levels and a higher grade of the tumor. Precise characteristics of the analyzed group are presented in Table 1.

Results of treatment in the whole *BRAF*+ group

Median overall survival (OS) and progression-free survival (PFS) in the whole analyzed group were 14.8 and 7.4 months, respectively. In monofactorial analysis unfavorable effects on OS and PFS were observed for metastases to the brain ($p < 0.0003$ and $p = 0.0071$, respectively), increased LDH levels ($p < 0.0001$ and $p = 0.0028$, respectively) and ECOG performance status > 1 ($p = 0.0002$ and $p = 0.0033$, respectively).

Table 1. Characteristics of patients in respect to first-line therapy used

Factors		IT n = 27 (20%)	TT n = 110 (80%)	p	Whole group n = 137
Age	Median (years)	59	58	0.5997	59
	≤ 65	20 (74%)	78 (71%)	0.9294	98 (72%)
	> 65	7 (26%)	32 (29%)		39 (28%)
Sex	Male	18 (67%)	60 (45%)	0.2497	78 (57%)
	Female	9 (33%)	50 (55%)		59 (43%)
Tumor stage	M1a	8 (26%)	15 (14%)	0.0096	23 (17%)
	M1b	7 (25%)	17 (15%)		24 (18%)
	M1c	10 (37%)	60 (55%)		70 (51%)
	M1d	2 (7%)	18 (16%)		20 (14%)
Presence of metastases to CNS	No	25 (96%)	92 (84%)	0.0071	127 (93%)
	Yes	2 (8%)	18 (16%)		20 (7%)
Number of metastatic sites	≤ 2	16 (59%)	50 (45%)	0.2840	66 (48%)
	> 2	11 (40%)	60 (55%)		71 (52%)
LDH	Normal	22(81%)	44 (40%)	0.0002	66 (48%)
	Above normal	5 (19%)	62 (56%)		67 (49%)
	No data	0 (0%)	4 (4%)		4 (3%)
LDH (×2)	≤ 2 × normal	26 (96%)	82 (78%)	0.0039	106 (81%)
	> 2 × normal	1 (4%)	24 (22%)		25 (19%)
ECOG/PS	0	4(15%)	11 (10%)	0,4326	15 (11%)
	1	22 (81%)	84 (76%)		106 (77%)
	2	1 (4%)	14 (13%)		15 (11%)
	3–4	0 (0%)	1 (1%)		1 (1%)
Localization of primary tumor	Skin	24 (89%)	91 (83%)	0,1337	115 (84%)
	Mucous membrane	1(4%)	0		1(1%)
	From unknown primary tumor location	2 (7%)	19 (17%)		21 (15%)

T — anti-PD-1 immunotherapy; TT — targeted therapy with BRAF ± MEK inhibitors; LDH — lactate dehydrogenase; CNS — central nervous system; ECOG/PS — performance status

The presence of metastases in > 2 sites had a statistically significant unfavorable effect only on OS ($p = 0.0113$). Sex, age > 65 years, location of the primary site did not have a statistically significant effect on OS and PFS.

Treatment results depending on the type of first line therapy TT vs. IT in *BRAF*+ patients

Median overall survival (OS) in the group receiving TT was 13.3 months whereas median OS was not attained in the IT group (median observation in the TT and IT groups was TT and IT 22 and 18 months, respectively). A statistically significant difference in OS was observed between groups treated with TT and IT ($p = 0.0011$) (Figure 1A) as well as between groups treated with *iBRAF* + *iMEK*, only *iBRAF* and IT

($p = 0.0084$) and *iBRAF* + *iMEK* vs. IT ($p = 0.0074$) (Figure 1B and 1C). A statistically significant difference was also observed in OS between the group receiving TT before 2017 ($p = 0.0071$) and the group treated with IT (Figure 1 D). There was no difference in OS between groups receiving TT before 2017 and from the beginning of 2017 ($p = 0.2634$) (Figure 1E). Median progression-free survival (PFS) in the groups receiving TT and IT were 7.2 and 9.0 months, respectively, and no statistically significant difference between them was observed ($p = 0.292$). Similarly, there was no statistically significant difference in PFS between the group receiving IT and the group treated with TT *iBRAF* + *iMEK* ($p = 0.1001$), as well as between the group receiving IT and the group treated only with TT before 2017 ($p = 0.3498$). A precise analysis of the




Figure 1. Kaplan-Meier survival curves. IT — anti-PD-1 immunotherapy; TT — targeted therapy with BRAF ± MEK inhibitors (iBRAF ± iMEK)

Table 2. Results of treatment depending on the first-line therapy used

Type of therapy	IT n = 27 (20%)	TT n = 110 (80%)	Total n = 137 (100%)
OS (median in months) p = 0.0011	Not reached	12.6 (6.7–24.6)	14.0 (7.2–31.2)
6-month OS	94%	76%	80%
1-year OS	81%	52%	57%
2-year OS	56%	26%	29%
PFS (median in months) p = 0.292	9.0 (3.7–26.6)	7.2 (4.2–12.7)	7.3 (4.1–14.4)
Response to treatment			
CR	4%	5%	4%
PR	41%	58%	55%
ORR (CR + PR)	45%	63%	59%
SD	44%	24%	29%
DCR (CR + PR + SD)	89%	77%	88%
PD	11%	13%	12%

IT — anti-PD-1 immunotherapy; TT — targeted therapy with BRAF ± MEK inhibitors; OS — overall; PFS — progression-free survival; CR — complete response; PR — partial response; SD — stable disease; PD — progression of disease; ORR — overall response rate; DCR — disease control rate

Table 3. Cox multifactorial analysis

Analyzed factors	PFS			OS		
	p	HR	CI	p	HR	CI
TT vs. IT	0.9768	1.0	0.6–1.7	0.0753	1.92	0.9–3.9
> 65 vs. ≤ 65	0.5618	0.88	0.6–1.4	0.5968	0.88	0.6–1.4
Female vs. male sex	0.7086	0.92	0.6–1.4	0.6881	0.91	0.6–1.4
Lack of metastases to CNS vs. metastases to CNS	0.0129	0.55	0.3–0.9	0.0021	0.46	0.3–0.8
Number of locations ≤ 2 vs. > 2	0.5334	1.15	0.7–1.8	0.7619	0.93	0.6–1.5
LDH normal vs. elevated	0.0150	0.58	0.4–0.9	0.0019	0.47	0.3–0.8
ECOG ≤ 1 vs. > 1	0.0013	0.38	0.2–0.7	< 0.001	0.28	0.2–0.5

T — anti-PD-1 immunotherapy; TT — targeted therapy with BRAF ± MEK inhibitors; LDH — lactate dehydrogenase; CNS — central nervous system; ECOG/PS — performance status

treatment results for group TT and IT is presented in Table 2. In multifactorial analysis a statistically significant unfavorable effect on OS and PFS was found for increased LDH levels, the presence of metastases to the CNS and ECOG > 1. The other factors were not statistically significant (Table 3).

Discussion

In the presented analysis a comparison was made between first-line IT or TT treatments in patients with advanced/metastatic melanoma with the *BRAF* muta-

tion. This is one of the very few analyses which encompass very homogeneous patient groups. All patients were treated in the frame of national drug programs and thus had to fulfil the same criteria for inclusion.

Among the first trials which determined the effectiveness of using immunotherapy before or after *iBRAF* were those performed by Ascierto et al. and Ackerman et al. [24, 25]. In these trials, ipilimumab was mainly used for immunotherapy and it was shown that immunotherapy administered before *iBRAF* does not decrease their effectiveness [24, 25]. Subsequent trials and (indirect) analyses confirmed that the use of immunotherapy in first-line treatment in patients with

a *BRAF* mutation could be a better option than targeted therapy [22, 23, 26].

Our analysis indicated higher effectiveness in first-line IT as compared to TT treatment in respect to OS ($p = 0.0011$) and lack of differences in respect to PFS ($p = 0.292$). This was, however, not confirmed in multifactorial analysis, which could be due to the small group receiving IT. Moser et al. and Schilling et al. who analyzed larger patient groups showed greater effectiveness in respect to OS for immunotherapy in first-line treatment in patients with advanced/metastatic melanoma with the *BRAF* mutation [20, 23]. In both these analyses, the OS for TT were similar (13.2 and 12.4 months) to our results (13.3 months) which indicates that the groups were similar and thus can confirm the similarity of the remaining results. It is worth mentioning that when immunotherapy was used in the BRAF+ group of the CheckMate067 trial, better results were obtained for combined anti-PD1 and anti-CTLA-4 immunotherapy than for anti-PD-1 monotherapy.

As recruitment of patients for IT treatment started in 2017, analysis of groups treated before 2017 and from 2017 was performed. The aim was to check if differences in OS between groups treated with TT and IT could be due to the fact that from 2017 patients with a worse prognosis qualified for TT treatment. No statistically significant difference was found for OS for patients receiving TT before and after 2017. A statistically significant difference was observed for patients treated with TT before 2017 and IT. The effectiveness of therapy with iBRAF, iBRAF + iMEK and IT was also compared. In all cases, IT was shown to prolong OS. It is worth noting that the results of treatment are worse in the analyzed group than in clinical trials, but better than in historical groups before new therapies were introduced.

Of course, our analysis has some limitations. First, it is retrospective, second, we compare small groups and moreover, they are unequal in size. Also, the fact that in the group receiving TT there were more patients with metastases to the CNS and elevated LDH levels (thus unfavorable prognostic factors) can affect the results of our analysis. Therefore, in order to unequivocally compare the effectiveness of TT and IT prospective, randomized trials should be conducted.

It can be stated with considerable certainty that in patients with advanced/metastatic melanoma with the *BRAF* mutation without rapid progression IT should be considered as first-line therapy.

Conflict of interest

Grants and consultancies:

Bożena Cybulska-Stopa — BMS, Novartis, Roche, Pierre Fabre, MSD; Karolina Piejko — MSD; Agata Sałek-Zań — BMS

References

- Zaleśna I, Hartman M, Czyż M. BRAF mutation in progression and therapy of melanoma, papillary thyroid carcinoma and colorectal adenocarcinoma. *Postepy Hig Med Dosw.* 2016; 70: 471–488, doi: [10.5604/17322693.1201719](https://doi.org/10.5604/17322693.1201719).
- Kakadia S, Yarlagađda N, Awad R, et al. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. *Onco Targets Ther.* 2018; 11: 7095–7107, doi: [10.2147/OTTS182721](https://doi.org/10.2147/OTTS182721), indexed in Pubmed: [30410366](https://pubmed.ncbi.nlm.nih.gov/30410366/).
- Chapman PB, Hauschild A, Robert C, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med.* 2011; 364(26): 2507–2516, doi: [10.1056/NEJMoa1103782](https://doi.org/10.1056/NEJMoa1103782), indexed in Pubmed: [21639808](https://pubmed.ncbi.nlm.nih.gov/21639808/).
- Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *Lancet.* 2012; 380(9839): 358–365, doi: [10.1016/S0140-6736\(12\)60868-X](https://doi.org/10.1016/S0140-6736(12)60868-X), indexed in Pubmed: [22735384](https://pubmed.ncbi.nlm.nih.gov/22735384/).
- Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. *N Engl J Med.* 2014; 371(20): 1867–1876, doi: [10.1056/NEJMoa1408868](https://doi.org/10.1056/NEJMoa1408868), indexed in Pubmed: [25265494](https://pubmed.ncbi.nlm.nih.gov/25265494/).
- Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. *Lancet.* 2015; 386(9992): 444–451, doi: [10.1016/S0140-6736\(15\)60898-4](https://doi.org/10.1016/S0140-6736(15)60898-4), indexed in Pubmed: [26037941](https://pubmed.ncbi.nlm.nih.gov/26037941/).
- Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. *N Engl J Med.* 2015; 372(1): 30–39, doi: [10.1056/NEJMoa1412690](https://doi.org/10.1056/NEJMoa1412690), indexed in Pubmed: [25399551](https://pubmed.ncbi.nlm.nih.gov/25399551/).
- Cybulska-Stopa B, Świtaj T, Koseta-Paterczyk H. Combined or sequential treatment of advanced melanoma? Nowotwory. *Journal of Oncology.* 2019; 69(3-4): 125–132, doi: [10.5603/njo.2019.0024](https://doi.org/10.5603/njo.2019.0024).
- Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. [Erratum appears in *N Engl J Med.* 2010 Sep 23;363(13):1290]. *N Engl J Med.* 2010; 363(8): 711–723.
- Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N Engl J Med.* 2011; 364(26): 2517–2526, doi: [10.1056/NEJMoa1104621](https://doi.org/10.1056/NEJMoa1104621), indexed in Pubmed: [21639810](https://pubmed.ncbi.nlm.nih.gov/21639810/).
- Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol.* 2015; 16(4): 375–384, doi: [10.1016/S1470-2045\(15\)70076-8](https://doi.org/10.1016/S1470-2045(15)70076-8), indexed in Pubmed: [25795410](https://pubmed.ncbi.nlm.nih.gov/25795410/).
- Larkin J, Minor D, D'Angelo S, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in checkmate 037: a randomized, controlled, open-label phase III trial. *J Clin Oncol.* 2018; 36(4): 383–390, doi: [10.1200/JCO.2016.71.8023](https://doi.org/10.1200/JCO.2016.71.8023), indexed in Pubmed: [28671856](https://pubmed.ncbi.nlm.nih.gov/28671856/).
- Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. *Lancet Oncol.* 2015; 16(8): 908–918, doi: [10.1016/S1470-2045\(15\)00083-2](https://doi.org/10.1016/S1470-2045(15)00083-2), indexed in Pubmed: [26115796](https://pubmed.ncbi.nlm.nih.gov/26115796/).
- Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. *Lancet Oncol.* 2019; 20(9): 1239–1251, doi: [10.1016/S1470-2045\(19\)30388-2](https://doi.org/10.1016/S1470-2045(19)30388-2), indexed in Pubmed: [31345627](https://pubmed.ncbi.nlm.nih.gov/31345627/).
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. *N Engl J Med.* 2015; 373(1): 23–34.
- Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. *N Engl J Med.* 2015; 372(21): 2006–2017, doi: [10.1056/NEJMoa1414428](https://doi.org/10.1056/NEJMoa1414428), indexed in Pubmed: [25891304](https://pubmed.ncbi.nlm.nih.gov/25891304/).
- Larkin J, Lao CD, Urba WJ, et al. Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. *JAMA Oncol.* 2015; 1(4): 433–440, doi: [10.1001/jamaoncol.2015.1184](https://doi.org/10.1001/jamaoncol.2015.1184), indexed in Pubmed: [26181250](https://pubmed.ncbi.nlm.nih.gov/26181250/).
- Shahabi V, Whitney G, Hamid O, et al. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. *Cancer Immunol Immunother.* 2012; 61(5): 733–737, doi: [10.1007/s00262-012-1227-3](https://doi.org/10.1007/s00262-012-1227-3), indexed in Pubmed: [22382362](https://pubmed.ncbi.nlm.nih.gov/22382362/).

19. Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. *Cancer Immunol Res.* 2014; 2(9): 846–856, doi: [10.1158/2326-6066.CCR-14-0040](https://doi.org/10.1158/2326-6066.CCR-14-0040), indexed in Pubmed: [24872026](https://pubmed.ncbi.nlm.nih.gov/24872026/).
20. Moser JC, Chen D, Hu-Lieskován S, et al. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab. *Cancer Med.* 2019; 8(18): 7637–7643, doi: [10.1002/cam4.2625](https://doi.org/10.1002/cam4.2625), indexed in Pubmed: [31677253](https://pubmed.ncbi.nlm.nih.gov/31677253/).
21. Devji T, Levine O, Neupane B, et al. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. *JAMA Oncol.* 2017; 3(3): 366–373, doi: [10.1001/jamaoncol.2016.4877](https://doi.org/10.1001/jamaoncol.2016.4877), indexed in Pubmed: [27787543](https://pubmed.ncbi.nlm.nih.gov/27787543/).
22. Wu M, Wang Y, Xu Y, et al. Indirect comparison between immune checkpoint inhibitors and targeted therapies for the treatment of melanoma. *J Cancer.* 2019; 10(24): 6114–6123, doi: [10.7150/jca.32638](https://doi.org/10.7150/jca.32638), indexed in Pubmed: [31762821](https://pubmed.ncbi.nlm.nih.gov/31762821/).
23. Schilling B, Martens A, Geukes Foppen MH, et al. First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. *Cancer Immunol Immunother.* 2019; 68(5): 765–772, doi: [10.1007/s00262-019-02311-1](https://doi.org/10.1007/s00262-019-02311-1), indexed in Pubmed: [30806748](https://pubmed.ncbi.nlm.nih.gov/30806748/).
24. Ascierto PA, Simeone E, Giannarelli D, et al. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. *J Transl Med.* 2012; 10: 107, doi: [10.1186/1479-5876-10-107](https://doi.org/10.1186/1479-5876-10-107), indexed in Pubmed: [22640478](https://pubmed.ncbi.nlm.nih.gov/22640478/).
25. Ackerman A, Klein O, McDermott DF, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. *Cancer.* 2014; 120(11): 1695–1701, doi: [10.1002/cncr.28620](https://doi.org/10.1002/cncr.28620), indexed in Pubmed: [24577748](https://pubmed.ncbi.nlm.nih.gov/24577748/).
26. Johnson DB, Pectasides E, Feld E, et al. Sequencing treatment in BRAFV600 mutant melanoma: anti-PD-1 before and after BRAF inhibition. *J Immunother.* 2017; 40(1): 31–35, doi: [10.1097/CJI.0000000000000148](https://doi.org/10.1097/CJI.0000000000000148), indexed in Pubmed: [27846054](https://pubmed.ncbi.nlm.nih.gov/27846054/).
27. National Cancer Institute. Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma. NLM Identifier: NCT02224781. <https://clinicaltrials.gov/ct2/show/NCT02224781> Accessed Januar 19, 2020.